These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11602791)

  • 21. Enhancement by polylysine of transient, but not stable, expression of genes carried into cells by polyoma VP1 pseudocapsids.
    Soeda E; Krauzewicz N; Cox C; Stokrová J; Forstová J; Griffin BE
    Gene Ther; 1998 Oct; 5(10):1410-9. PubMed ID: 9930347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice.
    Liu XS; Abdul-Jabbar I; Qi YM; Frazer IH; Zhou J
    Virology; 1998 Dec; 252(1):39-45. PubMed ID: 9875315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
    Park JS; Oh YK; Kang MJ; Kim CK
    J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The major capsid protein, VP1, of human JC virus expressed in Escherichia coli is able to self-assemble into a capsid-like particle and deliver exogenous DNA into human kidney cells.
    Ou WC; Wang M; Fung CY; Tsai RT; Chao PC; Hseu TH; Chang D
    J Gen Virol; 1999 Jan; 80 ( Pt 1)():39-46. PubMed ID: 9934681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.
    Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP
    J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection.
    Xu W; Shen Y; Jiang Z; Wang Y; Chu Y; Xiong S
    Vaccine; 2004 Sep; 22(27-28):3603-12. PubMed ID: 15315839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of recombinant virus-like particles of human and non-human polyomaviruses in yeast Saccharomyces cerevisiae.
    Sasnauskas K; Bulavaite A; Hale A; Jin L; Knowles WA; Gedvilaite A; Dargeviciūte A; Bartkeviciūte D; Zvirbliene A; Staniulis J; Brown DW; Ulrich R
    Intervirology; 2002; 45(4-6):308-17. PubMed ID: 12602348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-Cell-independent immunoglobulin G responses in vivo are elicited by live-virus infection but not by immunization with viral proteins or virus-like particles.
    Szomolanyi-Tsuda E; Le QP; Garcea RL; Welsh RM
    J Virol; 1998 Aug; 72(8):6665-70. PubMed ID: 9658113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation of monoclonal antibodies of desired specificity using chimeric polyomavirus-derived virus-like particles.
    Zvirbliene A; Samonskyte L; Gedvilaite A; Voronkova T; Ulrich R; Sasnauskas K
    J Immunol Methods; 2006 Apr; 311(1-2):57-70. PubMed ID: 16516908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A study of systems for delivering antigens and plasmid DNA for intranasal immunization against tick-borne encephalitis virus.
    Goncharova EP; Ryzhikov AB; Bulychev LE; Sizov AA; Lebedev LR; Poryvaev VD; Karpenko LI; Il'ichev AA
    Wien Klin Wochenschr; 2002 Jul; 114(13-14):630-5. PubMed ID: 12422616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lentivirus-like particles without reverse transcriptase elicit efficient immune responses.
    McBurney SP; Young KR; Nwaigwe CI; Soloff AC; Cole KS; Ross TM
    Curr HIV Res; 2006 Oct; 4(4):475-84. PubMed ID: 17073623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein.
    Gedvilaite A; Frömmel C; Sasnauskas K; Micheel B; Ozel M; Behrsing O; Staniulis J; Jandrig B; Scherneck S; Ulrich R
    Virology; 2000 Jul; 273(1):21-35. PubMed ID: 10891404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Trichodysplasia Spinulosa-Associated Polyomavirus Capsid Protein as a New Carrier for Construction of Chimeric Virus-Like Particles Harboring Foreign Epitopes.
    Gedvilaite A; Kucinskaite-Kodze I; Lasickiene R; Timinskas A; Vaitiekaite A; Ziogiene D; Zvirbliene A
    Viruses; 2015 Jul; 7(8):4204-29. PubMed ID: 26230706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric polyomavirus-derived virus-like particles: the immunogenicity of an inserted peptide applied without adjuvant to mice depends on its insertion site and its flanking linker sequence.
    Lawatscheck R; Aleksaite E; Schenk JA; Micheel B; Jandrig B; Holland G; Sasnauskas K; Gedvilaite A; Ulrich RG
    Viral Immunol; 2007 Sep; 20(3):453-60. PubMed ID: 17931115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity.
    Yao Q; Vuong V; Li M; Compans RW
    Vaccine; 2002 Jun; 20(19-20):2537-45. PubMed ID: 12057610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High immunogenicity of a hydrophilic component of the hepatitis B virus preS1 sequence exposed on the surface of three virus-like particle carriers.
    Skrastina D; Bulavaite A; Sominskaya I; Kovalevska L; Ose V; Priede D; Pumpens P; Sasnauskas K
    Vaccine; 2008 Apr; 26(16):1972-81. PubMed ID: 18343539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Type-specific and cross-reactive antibodies and T cell responses in norovirus VLP immunized mice are targeted both to conserved and variable domains of capsid VP1 protein.
    Malm M; Tamminen K; Vesikari T; Blazevic V
    Mol Immunol; 2016 Oct; 78():27-37. PubMed ID: 27573255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant.
    Oh YK; Sohn T; Park JS; Kang MJ; Choi HG; Kim JA; Kim WK; Ko JJ; Kim CK
    Virology; 2004 Oct; 328(2):266-73. PubMed ID: 15464846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bacterial magnetic particles (BMPs)-PEI as a novel and efficient non-viral gene delivery system.
    Xiang L; Bin W; Huali J; Wei J; Jiesheng T; Feng G; Ying L
    J Gene Med; 2007 Aug; 9(8):679-90. PubMed ID: 17605136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune responses generated by Lactobacillus as a carrier in DNA immunization against foot-and-mouth disease virus.
    Li YG; Tian FL; Gao FS; Tang XS; Xia C
    Vaccine; 2007 Jan; 25(5):902-11. PubMed ID: 17028078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.